Theravance Biopharma (NASDAQ:TBPH) received a $55.00 price objective from investment analysts at Cantor Fitzgerald in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 108.65% from the company’s current price.
The analysts wrote, “Positives from the quarter: 1) An sNDA was filed for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. TBPH is entitled to receive an 85% economic interest in the royalties paid by GSK (Not Covered) on worldwide net sales; 2) Trelegy Ellipta was granted marketing authorization in Europe for the treatment of COPD; 3) in November, TBPH and MYL (Neutral) announced the submission of an NDA for revefenacin (TD-4208) in adults with COPD; 4) at the 2017 Annual CHEST Meeting, TBPH and MYL announced the presentation of additional positive efficacy data from the three- month, pivotal Phase 3 studies of revefenacin (TD-4208); 5) progression of inhaled JAK inhibitor into first-in-human studies in late-2018/early-2019; 6) TBPH expects to provide an update in 1H18 regarding its dialogue with U.S. and EU regulators on Phase 3 requirements for the velusetrag/TD-5108 program in gastroparesis; 7) cash and equivalents totaled ~$390MM at 12/31/17. This excludes the $100MM upfront payment received in February 2018, from the announced collaboration with Janssen (Not Covered).””
Several other brokerages have also recently weighed in on TBPH. BidaskClub raised shares of Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 20th. Robert W. Baird reaffirmed a “sell” rating and set a $22.00 price target on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Leerink Swann raised their price target on shares of Theravance Biopharma from $45.00 to $48.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Needham & Company LLC reaffirmed a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, December 5th. Finally, ValuEngine cut shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Theravance Biopharma has an average rating of “Hold” and an average target price of $42.00.
Large investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. grew its stake in shares of Theravance Biopharma by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 230 shares in the last quarter. Moneta Group Investment Advisors LLC bought a new position in shares of Theravance Biopharma in the third quarter valued at $299,000. SG Americas Securities LLC grew its stake in shares of Theravance Biopharma by 52.8% in the third quarter. SG Americas Securities LLC now owns 9,061 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 3,130 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Theravance Biopharma in the fourth quarter valued at $313,000. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Theravance Biopharma by 1.5% in the second quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 217 shares in the last quarter. 85.75% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Theravance Biopharma (TBPH) Given a $55.00 Price Target by Cantor Fitzgerald Analysts” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3229794/theravance-biopharma-tbph-given-a-55-00-price-target-by-cantor-fitzgerald-analysts.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.